Literature DB >> 18435603

The business of RNAi therapeutics.

Dirk Haussecker1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18435603     DOI： 10.1089/hum.2008.007

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  15 in total

Review 1.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 2.  'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.

Authors:  Mei S Ong; Wanpei Cai; Yi Yuan; Hin C Leong; Tuan Z Tan; Asad Mohammad; Ming L You; Frank Arfuso; Boon C Goh; Sudha Warrier; Gautam Sethi; Nicholas S Tolwinski; Peter E Lobie; Celestial T Yap; Shing C Hooi; Ruby Y Huang; Alan P Kumar
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

3.  High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA.

Authors:  Bertrand Z Yeung; Ze Lu; Guillaume M Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2015-08-19       Impact factor: 4.009

4.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

5.  Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.

Authors:  Edwin H A Allen; Sarah D Atkinson; Haihui Liao; Jonathan E Moore; Deena M Leslie Pedrioli; Frances J D Smith; W H Irwin McLean; C B Tara Moore
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

6.  A status report on RNAi therapeutics.

Authors:  Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore
Journal:  Silence       Date:  2010-07-08

7.  VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA.

Authors:  Nishant Thakur; Abid Qureshi; Manoj Kumar
Journal:  Nucleic Acids Res       Date:  2011-12-01       Impact factor: 16.971

8.  The Business of RNAi Therapeutics in 2012.

Authors:  Dirk Haussecker
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-07       Impact factor: 10.183

9.  Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.

Authors:  Yeliz Utku Konca; Kent Kirshenbaum; Ronald N Zuckermann
Journal:  Int J Nanomedicine       Date:  2014-05-10

10.  U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo.

Authors:  Rafal Goraczniak; Brian A Wall; Mark A Behlke; Kim A Lennox; Eric S Ho; Nikolas H Zaphiros; Christopher Jakubowski; Neil R Patel; Steven Zhao; Carlo Magaway; Stacey A Subbie; Lumeng Jenny Yu; Stephanie Lacava; Kenneth R Reuhl; Suzie Chen; Samuel I Gunderson
Journal:  Mol Ther Nucleic Acids       Date:  2013-05-14       Impact factor: 10.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.